Dr. Martens plc (LON:DOCS - Get Free Report) shares shot up 24% during trading on Thursday . The company traded as high as GBX 76.40 ($1.03) and last traded at GBX 74.35 ($1.01). 7,443,822 shares were traded during trading, an increase of 232% from the average session volume of 2,245,163 shares. The stock had previously closed at GBX 59.95 ($0.81).
Analyst Ratings Changes
Separately, Royal Bank of Canada decreased their price objective on Dr. Martens from GBX 7,000 ($94.75) to GBX 6,000 ($81.21) and set a "sector perform" rating on the stock in a research note on Monday, May 19th.
Read Our Latest Analysis on DOCS
Dr. Martens Trading Up 8.7%
The company has a quick ratio of 1.13, a current ratio of 2.85 and a debt-to-equity ratio of 127.27. The firm has a market cap of £795.54 million, a price-to-earnings ratio of 11.62, a price-to-earnings-growth ratio of 6.40 and a beta of 0.11. The business has a 50 day moving average of GBX 55.34 and a 200 day moving average of GBX 62.91.
Dr. Martens (LON:DOCS - Get Free Report) last posted its quarterly earnings data on Thursday, June 5th. The company reported GBX 2.40 ($0.03) EPS for the quarter. Dr. Martens had a return on equity of 18.91% and a net margin of 7.89%. On average, research analysts forecast that Dr. Martens plc will post 2.5809394 earnings per share for the current fiscal year.
Dr. Martens Cuts Dividend
The firm also recently declared a dividend, which was paid on Tuesday, April 8th. Shareholders of record on Thursday, March 6th were paid a GBX 0.85 ($0.01) dividend. This represents a yield of 1.47%. The ex-dividend date was Thursday, March 6th. Dr. Martens's payout ratio is 42.53%.
Insiders Place Their Bets
In other news, insider Giles Wilson acquired 32,640 shares of Dr. Martens stock in a transaction dated Tuesday, March 25th. The shares were acquired at an average cost of GBX 54 ($0.73) per share, with a total value of £17,625.60 ($23,857.07). In the last ninety days, insiders have acquired 33,206 shares of company stock valued at $1,792,771. Insiders own 4.36% of the company's stock.
Dr. Martens Company Profile
(
Get Free Report)
Dr. Martens is an iconic British brand founded in 1960 in Northamptonshire. Originally produced for workers looking
for tough, durable boots, the brand was quickly adopted by diverse youth subcultures and associated musical
movements. Dr. Martens have since transcended their working-class roots while still celebrating their proud heritage
and, six decades later, “Docs” or “DMs” are worn by people around the world who use them as a symbol of
empowerment and their own individual attitude.
The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.
Featured Stories
Before you consider Dr. Martens, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Martens wasn't on the list.
While Dr. Martens currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
